PharmaCyte reports $17.7 million cash, $36.7 million assets
PharmaCyte Biotech (PMCB) reported $36.7M in total assets, including $17.7M in cash, and $27.5M in stockholders' equity as of July 31, 2026. The company plans to pursue investment opportunities and operational management, aiming to create shareholder value. PMCB focuses on developing cellular therapies for cancer, diabetes, and other diseases.
How this was made
The 30-second read
Why it matters
The disclosed cash level is modest relative to typical biotech development costs, suggesting the company may need external capital soon, which could affect share dilution risk.
Market read
Primary disclosure of a micro‑cap biotech's balance sheet; limited immediate trading impact but useful for liquidity assessment.
What to watch
Potential upcoming financing rounds or partnership announcements not covered in this filing.
Background
PharmaCyte Biotech (PMCB) is a Nasdaq‑listed micro‑cap focused on cellular therapies. The filing is its quarterly update after fiscal year‑end April 30.
Ticker impact
The article discloses PharmaCyte Biotech's latest balance sheet figures from its July 31, 2026 Form 10‑Q, including $17.7 M cash and $36.7 M total assets.
likely limited upside pressure as investors assess liquidity constraints
Small‑cap biotech with modest assets; no new product or partnership disclosed, so market reaction is expected to be muted.
Market effects
Provides a data point on cash balances for micro‑cap biotech peers, but unlikely to shift sector sentiment.
U.S. biotech micro‑cap segment only.
Limited to investors tracking small‑cap biotech balance sheets.
Counterpoint
If the cash burn rate is low, the modest balance sheet could be seen as a runway for upcoming clinical milestones.
Key entities
- ExecutiveJosh Silverman
Chief Executive Officer of PharmaCyte Biotech, quoted on balance sheet strength.
